Trial Search Results
Screening for Cervical Intraepithelial Neoplasia Using Self-collected Menstrual Blood
The purpose of this study is to investigate the feasibility and efficacy of assessing HR-HPV DNA and HPV E6/E7 mRNA via self-collected menstrual blood in a smart menstrual pad. In other words, can the investigators detect the high risk strains of the human papilloma virus (HPV) that are associated with cervical cancer in self-collected menstrual blood, as an alternative to collecting vaginal swabs.
Stanford is currently accepting patients for this trial.
- Diagnostic Test: Menstrual Blood Analysis (Menstrual Blood Analysis)
- Women in the age group 18-45 and
- who are menstruating and
- who have been tested HR-HPV positive and
- who can commit to have protected sex using condoms if they change sexual partners in
the time frame from self-collection and provider collected samples.
- Women younger than 18 years old or older than 45 years old or who are post menopausal
or not menstruating regularly and who are not HR-HPV positive and who cannot commit to
have protected sex using condoms if they change sexual partners in the time frame from
self-collection and provider collected samples.
Ages Eligible for Study
18 Years - 45 Years
Genders Eligible for Study